A phase II/III study of sotatercept (ACE-011), an activin antagonist, for chemotherapy-induced anemia in patients with metastatic non-small cell lung cancer treated with first-line platinum-based chemotherapy.
H. Raftopoulos
No relevant relationships to disclose
A. Laadem
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
M. Puccio
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
R. D. Knight
Employment or Leadership Position - Celgene
Stock Ownership - Celgene